Access Financial Services Inc. trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.4% in the fourth quarter, Holdings Channel reports. The fund owned 14,140 shares of the company’s stock after selling 345 shares during the period. Johnson & Johnson accounts for about 1.2% of Access Financial Services Inc.’s portfolio, making the stock its 17th biggest position. Access Financial Services Inc.’s holdings in Johnson & Johnson were worth $2,063,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. Verus Financial Partners Inc. grew its holdings in shares of Johnson & Johnson by 1.7% in the 4th quarter. Verus Financial Partners Inc. now owns 4,382 shares of the company’s stock worth $639,000 after acquiring an additional 74 shares during the period. Aries Wealth Management increased its stake in Johnson & Johnson by 0.3% in the 4th quarter. Aries Wealth Management now owns 27,932 shares of the company’s stock valued at $4,025,000 after purchasing an additional 75 shares in the last quarter. Portland Global Advisors LLC increased its stake in Johnson & Johnson by 0.9% in the 3rd quarter. Portland Global Advisors LLC now owns 8,744 shares of the company’s stock valued at $1,131,000 after purchasing an additional 78 shares in the last quarter. SRS Capital Advisors Inc. increased its stake in Johnson & Johnson by 0.5% in the 3rd quarter. SRS Capital Advisors Inc. now owns 17,452 shares of the company’s stock valued at $2,258,000 after purchasing an additional 79 shares in the last quarter. Finally, Arlington Partners LLC raised its holdings in Johnson & Johnson by 3.0% during the fourth quarter. Arlington Partners LLC now owns 2,790 shares of the company’s stock worth $407,000 after purchasing an additional 80 shares during the last quarter. Institutional investors own 67.36% of the company’s stock.
Shares of Johnson & Johnson stock opened at $149.27 on Wednesday. Johnson & Johnson has a 1 year low of $125.00 and a 1 year high of $150.17. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.26 and a quick ratio of 1.00. The business has a 50 day moving average price of $144.44 and a 200 day moving average price of $135.05. The company has a market capitalization of $392.60 billion, a P/E ratio of 23.32, a P/E/G ratio of 2.40 and a beta of 0.71.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 25th will be issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 2.55%. The ex-dividend date of this dividend is Monday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.
A number of research firms have commented on JNJ. Raymond James decreased their target price on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Cantor Fitzgerald initiated coverage on Johnson & Johnson in a research report on Wednesday, November 27th. They issued an “overweight” rating and a $160.00 price target for the company. Credit Suisse Group restated a “buy” rating and issued a $163.00 price target on shares of Johnson & Johnson in a research report on Tuesday, December 31st. Sanford C. Bernstein raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target for the company in a research note on Friday, October 11th. Finally, Barclays upgraded shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $140.00 to $173.00 in a research report on Thursday, December 19th. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Johnson & Johnson currently has an average rating of “Buy” and an average price target of $159.33.
In related news, Director Hubert Joly purchased 5,000 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was bought at an average cost of $141.28 per share, with a total value of $706,400.00. Following the completion of the acquisition, the director now directly owns 5,000 shares in the company, valued at approximately $706,400. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Kathryn E. Wengel sold 2,017 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $141.07, for a total value of $284,538.19. Following the completion of the sale, the executive vice president now owns 51,736 shares in the company, valued at $7,298,397.52. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: Trade War
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.